Anticonvulsant osteomalacia.

Abstract

Drug-induced osteomalacia appears to be a relatively common disorder in patients receiving long-term anticonvulsant drug therapy. The severity of clinical manifestations in any given individual appears to be a function of the combined effects of a variety of factors including drug type and total drug dose, dietary vitamin D intake, sunlight exposure, and physical activity level. Aided by the recent development of sensitive techniques such as the serum 25-hydroxyvitamin D assay and the photon absorption methods for bone mass determination, one can now detect abnormalities in vitamin D and bone metabolism with much greater precision. As a consequence, the incidence of disordered mineral metabolism in patients receiving long-term anti-convulsant therapy can be determined with greater precision and therapeutic regimens instituted to prevent the associated morbidity.

• Journal: Archives of internal medicine (Arch Intern Med) Vol. 135 Issue 7 Pg. 997-1000 (Jul 1975) ISSN: 0003-9926 [Print] United States
• PMID: 1156061 (Publication Type: Journal Article)

Chemical References

• Anticonvulsants
• Minerals
• Vitamin D
• Phenytoin
• Mephenytoin
• Phenobarbital

Topics

• Adolescent
• Anticonvulsants (adverse effects)
• Bone and Bones (metabolism)
• Humans
• Male
• Mephenytoin (adverse effects, therapeutic use)
• Minerals
• Osteomalacia (chemically induced)
• Phenobarbital (adverse effects, therapeutic use)
• Phenytoin (adverse effects, therapeutic use)
• Seizures (blood, drug therapy)
• Vitamin D (blood)